Clínic Barcelona. Hospital Universitari
<< More news


October 2, 2014

A proteomic study shows the critical role of Akt1 on promoting angiogenesis

A group of researchers from IDIBAPS headed by Dr. Manuel Morales-Ruiz, from the Biochemistry and Molecular Genetics department at Hospital Clínic and member of the IDIBAPS team Pathophysiology and treatment of ascites and altered renal function in liver cirrosis, have found the mechanism by which Akt1, an enzyme involved in the growth, survival and vascular tone of endothelial cells, promotes angiogenesis. The study has been carried out in collaboration with Yale University and published in the Proceedings of the National Academy of Sciences (PNAS) journal. In this paper has also participated Dr. Juan Rodriguez Vita, a postdoctoral researcher in Dr. Morales’ group hired through the BIOTRACK Programme, an IDIBAPS project to incorporate postdoctoral researchers funded by the European Commission through the Marie Curie Actions (COFUND category).

Angiogenesis is a physiological process through which new blood vessels are created form the pre-existing ones. It is a normal process during embryonic development, body growth and wound healing. However, it is also fundamental in fibrogenesis and tumor growth. Elucidating the mechanisms involved in this process is crucial to design strategies for the treatment of several diseases.

In mammals, there are three Akt isoforms encoded by three genes which share significant sequence homology and play a key role in the regulation of angiogenesis. These three forms have non-overlaping functions, although the mechanism for this Akt specificity has not been well understood until now. The article published at PNAS, focused on studying the differences between the Akt1 and Akt2 isoforms, identifies Akt1 as the predominant in promoting angiogenesis in the endothelium and influencing multiple signaling networks critical to the vascular growth. The deletion of Akt1 in the animal models used in the study caused abnormalities in vascular maturation and development, which does not happen when the isoform suppressed is Akt2.

This new information is clinically relevant considering the dual role of Akt as a key cell mediator in physiological and pathological conditions. From this proteomic study it will be possible the detection of new therapeutic targets and specific inhibitors, the identification of new biomarkers for pathological conditions and the generation of new therapeutic drugs with a better biosafety profile. Researcher are now focused on assessing the therapeutic potential of these targets of Akt on several pathologies such as chronic liver disease, metabolic disorders, atherosclerosis and cancer.

Article reference:

Lee MY, Luciano AK, Ackah E, Rodriguez-Vita J, Bancroft TA, Eichmann A, Simons M, Kyriakides TR, Morales-Ruiz M, Sessa WC.

ProcNatlAcadSci U S A. 2014 Aug 18. pii: 201408472. 


Biomedical Diagnostic Center (CDB)

Villarroel, 170 · 08036 Barcelona
Tel: +34 93 227 54 64 · Fax: +34 93 227 98 75 · ·